Q4 2025
Released Feb 3, 2026, before the open
10-K filed Feb 26, 2026, 57 days after period end · 0000078003-26-000026
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$17.56B$17.56B derived−1.2% vs Q4 2024+5.4% vs Q3 2025
Net Income-$1.65B-$1.65B derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived$5,348,000,000−20.4%
Free Cash Flowderived$4,503,000,000−22.4%
Margins · derived
Net margin-9.4%−11.7 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $17.56B | $17.76B | $5.93B | $15.75B |
| Net Income | -$1.65B | $410.00M | -$3.37B | $4.99B |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR